Thorsten K Oost

This inventor holds 60 USPTO granted patents and 23 published patent applications, plus 13 CIPO patents and 33 EPO patents, primarily in Pharmaceutical Chemistry (CPC class C07D). Top assignees: Boehringer Ingelheim International Gmbh, Abbott Gmbh & Co Kg, Abbvie Deutschland Gmbh and Co Kg. Active years: 2004-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thorsten K Oost. Retrieved from https://idiyas.com/inventor/thorsten-k-oost

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 60 (Patent Applications = 23)

% Patents Active = 51.7

CIPO Patents = 13 (Patent Applications = 10)

EPO Patents = 33 (Patent Applications = 36)

Average Co-Inventor Count = 6.0

ph-index = 13

Forward Citations = 420(Granted Patents)

Forward Citations (Not Self Cited) = 340(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Pleasant Prairie, WI (US) (2004 - 2009)
Ludwigshafen, DE (2010 - 2012)
Biberach, DE (2011 - 2015)
Heidelberg, DE (2011 - 2016)
Biberach an der Riss, DE (2010 - 2024)

Company Filing History:

30 out of 1,562

Boehringer Ingelheim International Gmbh

Abbvie Deutschland Gmbh and Co Kg

patents

4. 3 out of 4,189

Abbott Laboratories Corporation

6. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2024

Loading Chart...

Areas of Expertise:

Neutrophil Elastase Inhibitors

Oxindole Derivatives

TRPA1 Inhibitors

Cyclic Dinucleotide Compounds

Heterocyclic Compounds

Bicyclic Dihydropyrimidinones

Pyridone Derivatives

Cathepsin C Inhibitors

Pyrazole Compounds

Vasopressin Receptor Ligands

Anti-Obesity Agents

5-Halogen-Substituted Compounds

60 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12065427 - Heterocyclic compounds capable of activating STING (2024-08-20),

2. 11878981 - Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors (2024-01-23),

3. 10537590 - Cyclic dinucleotide compounds (2020-01-21),

4. 10392419 - Modified cyclic dinucleotide compounds (2019-08-27),

5. RE47493 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2019-07-08),

6. 10238633 - Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C (2019-03-26),

7. RE46630 - Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity (2017-12-11),

8. 9713606 - Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C (2017-07-25),

9. 9670166 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2017-06-06),

10. 9657015 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2017-05-23),

11. 9487505 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them (2016-11-08),

12. 9475779 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2016-10-25),

13. 9458113 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2016-10-04),

14. 9440930 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2016-09-13),

15. 9434713 - 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases (2016-09-06),

Title: Unveiling the Innovations of Thorsten K. Oost

Introduction: Thorsten K. Oost, a prolific inventor based in Heidelberg, Germany, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 59 patents.

Latest Patents: Among his recent patents, Thorsten K. Oost has introduced groundbreaking inventions such as "Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors." These derivatives serve as inhibitors of transient receptor potential ankyrin 1 (TRPA1), showcasing their potential in treating diseases where TRPA1 inhibition is beneficial. Additionally, his patent on "Cyclic dinucleotide compounds" highlights compounds that act as modulators of STING, providing promising pharmacological properties.

Career Highlights: Thorsten K. Oost has lent his expertise to renowned companies in the pharmaceutical industry, including Boehringer Ingelheim International GmbH and Abbott GmbH & Co. KG. His innovative mindset and dedication have been instrumental in driving advancements in drug discovery and development.

Collaborations: Throughout his career, Thorsten K. Oost has collaborated with esteemed professionals in the field, such as Liliane Unger and Wolfgang Wernet. These collaborations have led to synergistic efforts in research and development, ultimately resulting in groundbreaking inventions.

Conclusion: Thorsten K. Oost's relentless pursuit of innovation and his unwavering commitment to improving healthcare through his patents exemplify his remarkable contributions to the pharmaceutical landscape. His collaborations and career highlights underscore his position as a visionary inventor shaping the future of pharmaceuticals.

Profile summary based on public USPTO records.